Inflammation resolution, neuroprotection, and brain repair to promote stroke recovery

炎症消解、神经保护和大脑修复以促进中风康复

基本信息

  • 批准号:
    10261320
  • 负责人:
  • 金额:
    $ 40.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-08-15 至 2022-05-31
  • 项目状态:
    已结题

项目摘要

Accumulating evidence implicates inflammation and immune responses in the pathophysiology of stroke. Immunomodulation has therefore emerged as a promising therapy for stroke. Regulatory lymphocytes, including CD4+CD25+ regulatory T cells (CD4+ Treg) and IL-10+ regulatory B cells (Bregs) are established modulators of immune responses in the injured brain. We recently discovered that another specialized T cell subpopulation—the CD8+CD122+CD49dhigh regulatory T cell—is among the first to enter the ischemic brain, even preceding the infiltration of CD4+ Tregs and Bregs. The primary function of CD8+ Tregs is to modulate the activities of other immune cells, especially effector T lymphocytes, and to maintain immune homeostasis. We found that selective depletion of circulating CD8+ Tregs exacerbated brain injury and functional outcomes at 3 and 7 days after stroke, and this could be reversed by the reconstitution of CD8+ Tregs. These exciting results suggest that CD8+ Tregs are natural defenders against ischemic brain injury. Further pilot studies discovered that: 1) CD8+ Treg-afforded early protection relies on their infiltration into the ischemic brain, as CD8+ Tregs lacking the “brain targeting signal” CXCR3 do not infiltrate into the ischemic brain and lose their capacity to reduce brain infarction in CD8+ Treg-depleted mice. 2) The infiltrated CD8+ Tregs undergo genomic reprogramming upon brain infiltration and transcriptional upregulation of a group of genes that possess inflammation-resolving and/or neurorestorative functions, including the leukemia inhibitory factor (LIF) receptor and epidermal growth factor-like transforming growth factor (ETGF). 3) Post-stroke adoptive transfer of CD8+ Tregs significantly reduces brain infarct, enhances white matter integrity, and improves neurological functions up to 14d after tMCAO. 4) Adoptive transfer of ETGF-deficient CD8+ Treg fails to protect against tMCAO. The current proposal will further explore the effects of CD8+ Tregs in ischemic stroke and develop CD8+ Treg adoptive transfer as an immune therapeutic therapy for stroke. The novel central hypothesis to be tested is that brain infiltration of CD8+ Tregs promotes long-term neurological recovery after stroke through LIF/LIFR/ETGF-mediated neuroprotection, resolution of neuroinflammation, and neurorestorative mechanisms. Three specific aims are proposed. Aim 1. Establish post-stroke adoptive transfer of CD8+ Tregs as a clinically relevant treatment against acute ischemic brain infarct. Aim 2. Test the hypothesis that post-stroke adoptive transfer of CD8+ Tregs promotes long-term neurological recovery and neurorestoration after ischemic stroke. Aim 3. Test the hypothesis that LIF/LIFR-mediated release of ETGF is essential for CD8+ Treg-afforded neuroprotection and neurorestoration. This study will be the first to rigorously investigate the role of CD8+ Tregs in ischemic brain injury. The results will improve our understanding of stroke immunomodulation and shed light on CD8+ Treg transfer as a potential therapeutic strategy.
越来越多的证据表明炎症和免疫反应与脑血管病的病理生理学有关 卒中。因此,免疫调节疗法已成为治疗中风的一种很有前途的疗法。监管 淋巴细胞,包括CD4+CD25+调节性T细胞(CD4+Treg)和IL-10+调节性B细胞(Bregs) 在受伤的大脑中建立了免疫反应的调节器。我们最近发现,另一个 专门的T细胞亚群-CD8+CD122+CD49d高调节性T细胞-是最早进入的 脑缺血,甚至先于CD4+Tregs和Bregs的渗透。CD8+的主要功能 Tregs是调节其他免疫细胞,特别是效应性T淋巴细胞的活性,并维持 免疫动态平衡。我们发现选择性地耗尽循环中的CD8+Tregs会加重脑损伤 和卒中后3天和7天的功能结果,这种情况可以通过重建 CD8+树突状细胞。这些令人兴奋的结果表明,CD8+Tregs是脑缺血的天然防御者 受伤。进一步的初步研究发现:1)CD8+Treg的早期保护依赖于它们的渗透 由于CD8+Tregs缺乏“脑靶向信号”,CXCR3不会渗透到缺血的大脑中。 在CD8+Treg耗尽的小鼠中,它们可以减少脑缺血,并失去减少脑梗塞的能力。2) 浸润性CD8+Tregs在脑内渗透和转录时进行基因组重编程 一组具有消炎和/或神经恢复功能的基因上调, 包括白血病抑制因子(LIF)受体和表皮生长因子样转化生长 因子(ETGF)。3)卒中后CD8+Tregs过继转移明显减少脑梗塞,增强 白质完整性,并改善神经功能,直到tMCAO后14d。4)收养转让 ETGF缺乏的CD8+Treg不能预防tMCAO。目前的提案将进一步探讨其影响 CD8+Treg在缺血性卒中中的应用及CD8+Treg过继转移作为免疫治疗的研究 治疗中风。有待检验的新中心假设是,CD8+Tregs的大脑渗透促进了 卒中后通过LIF/LIFR/ETGF介导的神经保护的长期神经恢复,解决 神经炎症和神经恢复机制。提出了三个具体目标。目标1.建立 卒中后CD8+Tregs过继移植治疗急性脑缺血的临床研究 脑梗塞。目的2.验证中风后CD8+Tregs过继移植促进长期治疗的假说 缺血性卒中后的神经功能恢复和神经功能恢复。目标3.检验假设 LiF/LIFR介导的ETGF释放对CD8+Treg提供的神经保护和 神经修复。这项研究将首次严格研究CD8+Tregs在脑缺血中的作用 受伤。这一结果将提高我们对中风免疫调节的理解,并为CD8+Treg的研究提供线索 转移作为一种潜在的治疗策略。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jun Chen其他文献

Corrosion wear characteristics of TC4, 316 stainless steel, and Monel K500 in artificial seawater
TC4、316不锈钢、蒙乃尔K500在人工海水中的腐蚀磨损特性
  • DOI:
    10.1039/c7ra03065g
  • 发表时间:
    2017-04
  • 期刊:
  • 影响因子:
    3.9
  • 作者:
    Jun Chen
  • 通讯作者:
    Jun Chen

Jun Chen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jun Chen', 18)}}的其他基金

BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10696455
  • 财政年份:
    2023
  • 资助金额:
    $ 40.83万
  • 项目类别:
Adiponectin on cerebrovascular regulation in vascular cognitive impairment and dementia (VCID)
脂联素对血管性认知障碍和痴呆 (VCID) 的脑血管调节作用
  • 批准号:
    10542359
  • 财政年份:
    2022
  • 资助金额:
    $ 40.83万
  • 项目类别:
Activation of the RXR/PPARγ axis improves long-term outcomes after ischemic stroke in aged mice
RXR/PPARγ 轴的激活可改善老年小鼠缺血性中风后的长期结果
  • 批准号:
    10364171
  • 财政年份:
    2022
  • 资助金额:
    $ 40.83万
  • 项目类别:
Activation of the RXR/PPARγ axis improves long-term outcomes after ischemic stroke in aged mice
RXR/PPARγ 轴的激活可改善老年小鼠缺血性中风后的长期结果
  • 批准号:
    10609791
  • 财政年份:
    2022
  • 资助金额:
    $ 40.83万
  • 项目类别:
Methods for microbiome compositional data
微生物组组成数据的方法
  • 批准号:
    10338342
  • 财政年份:
    2022
  • 资助金额:
    $ 40.83万
  • 项目类别:
Methods for microbiome compositional data
微生物组组成数据的方法
  • 批准号:
    10580718
  • 财政年份:
    2022
  • 资助金额:
    $ 40.83万
  • 项目类别:
Methods for Analysis of Genomic Data with Auxiliary Information
具有辅助信息的基因组数据分析方法
  • 批准号:
    10188885
  • 财政年份:
    2021
  • 资助金额:
    $ 40.83万
  • 项目类别:
Methods for Analysis of Genomic Data with Auxiliary Information
具有辅助信息的基因组数据分析方法
  • 批准号:
    10415152
  • 财政年份:
    2021
  • 资助金额:
    $ 40.83万
  • 项目类别:
Inflammation resolution, neuroprotection, and brain repair to promote stroke recovery
炎症消解、神经保护和大脑修复以促进中风康复
  • 批准号:
    9471926
  • 财政年份:
    2017
  • 资助金额:
    $ 40.83万
  • 项目类别:
Inflammation resolution, neuroprotection, and brain repair to promote stroke recovery
炎症消解、神经保护和大脑修复以促进中风康复
  • 批准号:
    9697886
  • 财政年份:
    2017
  • 资助金额:
    $ 40.83万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.83万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.83万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 40.83万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.83万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.83万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.83万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.83万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 40.83万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 40.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 40.83万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了